Starpharma (OTCMKTS:SPHRY) vs. OneMedNet (NASDAQ:ONMD) Critical Survey

Volatility and Risk

OneMedNet has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Starpharma has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500.

Insider & Institutional Ownership

0.9% of OneMedNet shares are owned by institutional investors. 44.7% of OneMedNet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares OneMedNet and Starpharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OneMedNet	$957,651.00	28.93	-$33.78 million	N/A	N/A
Starpharma	$6.40 million	4.91	-$5.36 million	N/A	N/A

Starpharma has higher revenue and earnings than OneMedNet.

Profitability

This table compares OneMedNet and Starpharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OneMedNet	-1,093.61%	N/A	-640.55%
Starpharma	N/A	N/A	N/A

Summary

Starpharma beats OneMedNet on 5 of the 8 factors compared between the two stocks.

About OneMedNet

OneMedNet Corporation provides clinical imaging solutions. It offers iRWD, a solution that utilizes AI to securely de-identify, search, and curate imaging data for its partner network consisting of medical and academic research institutions to generate progression in stages of medical research, discovery and diagnostics that span the field of life sciences. OneMedNet Corporation is based in Eden Prairie, Minnesota.

About Starpharma

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.